Product Development
Dry Eye Disease
Restorative Biosciences is currently developing a prescription therapeutic for Chronic Dry Eye (keratoconjunctivitis sicca). Dry Eye affects over 30 million people in America and is growing at a double digit rate. It is estimated that Dry Eye product sales for prescription-based and OTC exceed $500 million annually.
In healthy eyes, normal tear production protects the surface of the eye and keeps it properly lubricated. The tear film is a complex mixture of water, fatty oils, proteins, electrolytes, bacteria-fighting substances and growth factors all interacting to allow smooth functioning and clear vision. As the tear film destabilizes, a stinging, burning, itchy and general dryness feeling arises in the eye. The cause of this tear imbalance is inflammation. The inflammation response can be brought on by medications and other environmental stresses.
Restorative Biosciences' pilot product targets this underlying inflammation in the lacrimal glands and corneal surface thus increasing tear production while simultaneously restoring the tear film on the cornea. In the first few minutes, over 95% of typical OTC Dry Eye therapeutics wash away. Restorative Biosciences' product is able to persist on the surface allowing time for tear film restoration.
Ophthalmic Medical Device Coatings
Restorative Biosciences has recently entered a development agreement that will initially focus on device coatings for the ophthalmic medical device market. The technology works by halting the underlying inflammatory and bacterial causes of these device failures. Contact lens, surgical, refractive surgical, and dry eye applications will be targeted with these ongoing developments.
Additional Applications
As Restorative Biosciences' therapeutics and medical device coatings technologies advance, additional areas with pathologies rooted in inflammation are being pursued. These areas include medical device coatings for non-ophthalmic chronic implants and therapies for cardiovascular disease and cancer.
